• ‘How do you decide?': Cancer treatment's CAR-T crisis has patients dying on a wait list

    29 days ago - By STAT

    Within two years of being diagnosed with multiple myeloma, Shawn Goltzene had blasted through nearly all his options. An initial stem cell transplant couldn't hold off the cancer for more than half a year. With each new therapy his doctors tried, the cancer would surge out of remission within weeks - striking the bones in his back and legs.
    “We hit him with everything, the whole kitchen sink,” said Krina Patel, the director of the myeloma cell therapy program at MD Anderson Cancer Center and Goltzene's clinician. She tried putting him on a clinical trial for an immunotherapy drug. “It blew...
    Read more ...

     

  • STAT+: Companies can't make CAR-T cells for cancer treatment quickly enough. Here's what they're doing about it

    29 days ago - By STAT

    The shortage of manufacturing slots for CAR-T cells, which has left myeloma patients dying on a wait list , came as a surprise to drugmakers and clinicians alike.
    When the Food and Drug Administration approved the first myeloma CAR-T product from Bristol Myers Squibb in spring of 2021, there were already four other lymphoma and leukemia CAR-T therapies on the market. Those weren't facing severe supply constraints so people hadn't expected there to be issues supplying ide-cel, Bristol's myeloma CAR-T, said Yi Lin, the director of the cell therapy program at the Mayo Clinic. But after the...
    Read more ...